États-Unis · Bourse & Finance · Investor's Business Daily

Uniqure Plummets 37% On Another Shocking Twist For Its Huntington's Drug

Publié par Investor's Business Daily · États-Unis il y a 12 h

Uniqure stock crashed Tuesday on a disappointing four-year update for its gene therapy in patients with Huntington's disease.

Lire l'article complet sur Investor's Business Daily Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.investors.com)

À lire aussi

Binance Pay lets visitors spend USDT at PayPay merchants in Japan

Shell-led LNG Canada to proceed with Phase 2 expansion, doubling export capacity

China factory activity snaps 2-month contractionary streak in September

Business Insider

Paramount's streaming chief is out ahead of the WBD merger. Read the memo she sent to staff.

A.I. Is ‘Better Informed’ Than Doctors, Kennedy Tells Industry-Backed MAHA Summit

Oil's New Normal Is Higher Prices